Subject: Specialty Quantity Limit Lumakras 4772-H P2023
Policy:
I. PROGRAM DESCRIPTION
The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.
II. COVERED QUANTITIES
|
Medication
|
Standard Limit
|
FDA-recommended dosing
|
|
Lumakras (sotorasib)
120 mg tablets
|
240 per 30 days
|
Recommended dosage: 960 mg (eight 120 mg
tablets or three 320 mg tablets) orally once daily.
Dosage modifications may be necessary for
adverse reactions.
|
|
Lumakras (sotorasib)
320 mg tablets
|
90 per 30 days
|
Place of Service:
Outpatient
The above policy is based on the following references:
- Lumakras [package insert]. Thousand Oaks, CA: Amgen Inc.; January 2023.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
August 18, 2023
